Clinical Trial Update: Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating pyrotinib plus trastuzumab after first-line therapy in HER-2 positive advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Fujian Medical University Union Hospital | Conditions: Advanced Breast Cancer | Phase 2 | Status: UNKNOWN